provides Immutep and its potential partners flexibility for...

provides Immutep and its potential partners flexibility for late-stage clinical provides Immutep and its potential partners flexibility for late-stage clinical An amazing announcement though. There certainly aren’t any other Australian cancer focused biotechs that are in phase 3 (even if IMM doesn’t proceed with MBC/TNBC it’s still an amazing achievement). And to have it as a phase 2/3 no less - which expedites the whole trial.

but here we are - an amazing 1.75% increase in the share price. Other companies it would’ve meant a 100% re-rate.

a positive in the announcement at least is the reference that it provides “potential partners flexibility of late stage clinical development”.

have a great Christmas everyone and here’s hoping for a better 2023 for long suffering shareholders